PMID- 35968361
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220816
IS  - 1662-4548 (Print)
IS  - 1662-453X (Electronic)
IS  - 1662-453X (Linking)
VI  - 16
DP  - 2022
TI  - The CX-DZ-II intelligent electronic stimulator for neck pain caused by cervical 
      spondylosis: A two-center, randomized, controlled, and non-inferiority trial.
PG  - 910574
LID - 10.3389/fnins.2022.910574 [doi]
LID - 910574
AB  - BACKGROUND: Electroacupuncture (EA) has been commonly used for the management of 
      neck pain caused by cervical spondylosis (NPCS); however, current electrical 
      instruments have limitations on intelligence, digitalization, and visualization. 
      The intelligent electronic stimulator (CX-DZ-II) is a digital device with an 
      evidence-based diagnosis and treatment system. This study aimed to investigate 
      the efficacy and safety of the CX-DZ-II intelligent EA instrument for NPCS. 
      MATERIALS AND METHODS: A total of 164 patients with NPCS [mean age (SD), 49.48 
      (13.47) years] were randomly assigned to receive 8 sessions (over 2 weeks) EA of 
      the intelligent electronic stimulator (CX-DZ-II) or the regular electronic 
      stimulator (SDZ-II). The primary outcome was the change of the visual analog 
      scale (VAS) from baseline to 2 weeks of treatment. Secondary outcomes included 
      mean scores of the VAS after each treatment in 1 week, responder rate, drug-usage 
      rate of non-steroidal antipyretic analgesics (NSAAs), the occurrence rate of 
      adverse events (AEs), proportions of apparatus with defect during treatment, and 
      excellent rate of apparatus. RESULTS: The intelligent electronic stimulator 
      (CX-DZ-II) was non-inferior to the regular electronic stimulator (SDZ-II) for 
      changes from baseline in the VAS [3.36 vs. 3.23, with a difference of 0.17 (95% 
      CI, -0.36 to 0.69), P < 0.025 for non-inferiority]. No between-group differences 
      were found in outcomes of VAS in 1 week, overall responders, and drug-usage rate 
      of NSAAs. The defect rate and excellent rate of the instrument were similar in 
      the CX-DZ-II and SDZ-II groups. Adverse events occurred in 9 (10.84%) patients in 
      the CX-DZ-II group and 4 (5.00%) patients in the SDZ-II group. CONCLUSION: The 
      intelligent electronic stimulator (CX-DZ-II) was non-inferior to the regular 
      electronic stimulator (SDZ-II) in relieving neck pain. The intelligent electronic 
      stimulator (CX-DZ-II) is a promising non-inferior alternative instrument for 
      NPCS. CLINICAL TRIAL REGISTRATION: [https://clinicaltrials.gov/], identifier 
      [NCT030 05301].
CI  - Copyright (c) 2022 Chen, Li, Xu, Liang, Zhang, Ren and Liang.
FAU - Chen, Liping
AU  - Chen L
AD  - College of Acupuncture Moxibustion and Tuina, Chengdu University of Traditional 
      Chinese Medicine, Chengdu, China.
FAU - Li, Dehua
AU  - Li D
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Xu, Jing
AU  - Xu J
AD  - College of Acupuncture Moxibustion and Tuina, Chengdu University of Traditional 
      Chinese Medicine, Chengdu, China.
FAU - Liang, Hao
AU  - Liang H
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Zhang, Ya
AU  - Zhang Y
AD  - College of Acupuncture Moxibustion and Tuina, Chengdu University of Traditional 
      Chinese Medicine, Chengdu, China.
FAU - Ren, Yulan
AU  - Ren Y
AD  - College of Chinese Classics, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, China.
FAU - Liang, Fanrong
AU  - Liang F
AD  - College of Acupuncture Moxibustion and Tuina, Chengdu University of Traditional 
      Chinese Medicine, Chengdu, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT00000030
PT  - Journal Article
DEP - 20220728
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC9366011
OTO - NOTNLM
OT  - cervical spondylosis
OT  - electroacupuncture
OT  - neck pain
OT  - non-inferiority trial
OT  - randomized controlled trial
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/16 06:00
MHDA- 2022/08/16 06:01
PMCR- 2022/01/01
CRDT- 2022/08/15 04:13
PHST- 2022/04/01 00:00 [received]
PHST- 2022/06/28 00:00 [accepted]
PHST- 2022/08/15 04:13 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/16 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fnins.2022.910574 [doi]
PST - epublish
SO  - Front Neurosci. 2022 Jul 28;16:910574. doi: 10.3389/fnins.2022.910574. 
      eCollection 2022.